These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34698501)

  • 1. GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults.
    Lanini S; Capone S; Antinori A; Milleri S; Nicastri E; Camerini R; Agrati C; Castilletti C; Mori F; Sacchi A; Matusali G; Gagliardini R; Ammendola V; Cimini E; Grazioli F; Scorzolini L; Napolitano F; Plazzi MM; Soriani M; De Luca A; Battella S; Sommella A; Contino AM; Barra F; Gentile M; Raggioli A; Shi Y; Girardi E; Maeurer M; Capobianchi MR; Vaia F; Piacentini M; Kroemer G; Vitelli A; Colloca S; Folgori A; Ippolito G
    Sci Transl Med; 2022 Jan; 14(627):eabj1996. PubMed ID: 34698501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19.
    Capone S; Raggioli A; Gentile M; Battella S; Lahm A; Sommella A; Contino AM; Urbanowicz RA; Scala R; Barra F; Leuzzi A; Lilli E; Miselli G; Noto A; Ferraiuolo M; Talotta F; Tsoleridis T; Castilletti C; Matusali G; Colavita F; Lapa D; Meschi S; Capobianchi M; Soriani M; Folgori A; Ball JK; Colloca S; Vitelli A
    Mol Ther; 2021 Aug; 29(8):2412-2423. PubMed ID: 33895322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
    Capone S; Fusco FM; Milleri S; Borrè S; Carbonara S; Lo Caputo S; Leone S; Gori G; Maggi P; Cascio A; Lichtner M; Cauda R; Dal Zoppo S; Cossu MV; Gori A; Roda S; Confalonieri P; Bonora S; Missale G; Codeluppi M; Mezzaroma I; Capici S; Pontali E; Libanore M; Diani A; Lanini S; Battella S; Contino AM; Piano Mortari E; Genova F; Parente G; Dragonetti R; Colloca S; Visani L; Iannacone C; Carsetti R; Folgori A; Camerini R;
    Cell Rep Med; 2023 Jun; 4(6):101084. PubMed ID: 37315558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
    N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results.
    Agrati C; Castilletti C; Battella S; Cimini E; Matusali G; Sommella A; Sacchi A; Colavita F; Contino AM; Bordoni V; Meschi S; Gramigna G; Barra F; Grassi G; Bordi L; Lapa D; Notari S; Casetti R; Bettini A; Francalancia M; Ciufoli F; Vergori A; Vita S; Gentile M; Raggioli A; Plazzi MM; Bacchieri A; Nicastri E; Antinori A; Milleri S; Lanini S; Colloca S; Girardi E; Camerini R; Ippolito G; Vaia F; Folgori A; Capone S
    NPJ Vaccines; 2022 Sep; 7(1):111. PubMed ID: 36153335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
    Anderson EJ; Rouphael NG; Widge AT; Jackson LA; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Corbett KS; Swanson PA; Padilla M; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Martinez DR; Baric R; Buchanan W; Luke CJ; Phadke VK; Rostad CA; Ledgerwood JE; Graham BS; Beigel JH;
    N Engl J Med; 2020 Dec; 383(25):2427-2438. PubMed ID: 32991794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
    Li J; Hui A; Zhang X; Yang Y; Tang R; Ye H; Ji R; Lin M; Zhu Z; Türeci Ö; Lagkadinou E; Jia S; Pan H; Peng F; Ma Z; Wu Z; Guo X; Shi Y; Muik A; Şahin U; Zhu L; Zhu F
    Nat Med; 2021 Jun; 27(6):1062-1070. PubMed ID: 33888900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
    Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
    Front Immunol; 2021; 12():697074. PubMed ID: 34262569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model.
    Johnson S; Martinez CI; Tedjakusuma SN; Peinovich N; Dora EG; Birch SM; Kajon AE; Werts AD; Tucker SN
    J Infect Dis; 2022 Jan; 225(1):34-41. PubMed ID: 34758086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
    Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates.
    Moliva JI; Andrew SF; Flynn BJ; Wagner DA; Foulds KE; Gagne M; Flebbe DR; Lamb E; Provost S; Marquez J; Mychalowych A; Lorag CG; Honeycutt CC; Burnett MR; McCormick L; Henry AR; Godbole S; Davis-Gardner ME; Minai M; Bock KW; Nagata BM; Todd JM; McCarthy E; Dodson A; Kouneski K; Cook A; Pessaint L; Ry AV; Valentin D; Young S; Littman Y; Boon ACM; Suthar MS; Lewis MG; Andersen H; Alves DA; Woodward R; Leuzzi A; Vitelli A; Colloca S; Folgori A; Raggiolli A; Capone S; Nason MC; Douek DC; Roederer M; Seder RA; Sullivan NJ
    bioRxiv; 2023 Nov; ():. PubMed ID: 38076895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccine BNT162b1 elicits human antibody and T
    Sahin U; Muik A; Derhovanessian E; Vogler I; Kranz LM; Vormehr M; Baum A; Pascal K; Quandt J; Maurus D; Brachtendorf S; Lörks V; Sikorski J; Hilker R; Becker D; Eller AK; Grützner J; Boesler C; Rosenbaum C; Kühnle MC; Luxemburger U; Kemmer-Brück A; Langer D; Bexon M; Bolte S; Karikó K; Palanche T; Fischer B; Schultz A; Shi PY; Fontes-Garfias C; Perez JL; Swanson KA; Loschko J; Scully IL; Cutler M; Kalina W; Kyratsous CA; Cooper D; Dormitzer PR; Jansen KU; Türeci Ö
    Nature; 2020 Oct; 586(7830):594-599. PubMed ID: 32998157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
    Modjarrad K; Roberts CC; Mills KT; Castellano AR; Paolino K; Muthumani K; Reuschel EL; Robb ML; Racine T; Oh MD; Lamarre C; Zaidi FI; Boyer J; Kudchodkar SB; Jeong M; Darden JM; Park YK; Scott PT; Remigio C; Parikh AP; Wise MC; Patel A; Duperret EK; Kim KY; Choi H; White S; Bagarazzi M; May JM; Kane D; Lee H; Kobinger G; Michael NL; Weiner DB; Thomas SJ; Maslow JN
    Lancet Infect Dis; 2019 Sep; 19(9):1013-1022. PubMed ID: 31351922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
    Frenck RW; Klein NP; Kitchin N; Gurtman A; Absalon J; Lockhart S; Perez JL; Walter EB; Senders S; Bailey R; Swanson KA; Ma H; Xu X; Koury K; Kalina WV; Cooper D; Jennings T; Brandon DM; Thomas SJ; Türeci Ö; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
    N Engl J Med; 2021 Jul; 385(3):239-250. PubMed ID: 34043894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.